Pancreatic Cancer Vaccine Breakthrough

The first person to receive the vaccine has remained cancer-free for six years, providing hope for a disease that typically has a very low survival rate.

Researchers believe the mRNA technology can be adapted to treat various types of cancer by training the immune system to recognize and attack malignant cells.

While the results are from a small initial study, they represent a significant step toward more effective and personalized cancer therapies.

Further large-scale clinical trials are planned to confirm the vaccine's efficacy and safety.